Tous Actualités
Suivre
Abonner Eli Lilly and Company

Eli Lilly and Company

Making Science Personal: Lilly Oncology to Unveil 76 Studies at ASCO 2007

Indianapolis (ots/PRNewswire)

- 37 Thoracic Cancer Studies; 11 Breast Cancer Studies; 9 Targeted
Agent Studies
Lilly Oncology will unveil 76 studies at the 43rd Annual Meeting
of the American Society of Clinical Oncology (ASCO) in Chicago, Ill.
from June 1-5, 2007. The company will present important data on
GEMZAR(R) (gemcitabine HCl for injection), ALIMTA(R) (pemetrexed for
injection), and enzastaurin, an investigational, oral, targeted
therapy. There will also be numerous studies that continue to use
GEMZAR and ALIMTA as chemotherapeutic foundations in innovative
combinations with new targeted therapies.
"This is an exciting time in cancer research as we are moving away
from 'one-size fits all' treatment," said Richard Gaynor, M.D., Lilly
vice president, cancer research and global oncology platform leader.
"Lilly's commitment to finding the right drug, at the right dose, for
the right patient at the right time will be demonstrated at ASCO this
year."
    Key Lilly Abstracts for ASCO 2007:
    -- ALIMTA(R) (pemetrexed for injection)
        -- Phase III Study of ALIMTA in First-line NSCLC
            -- Abstract # 7517: June 2, 2007; 3:00 p.m.
            -- Pemetrexed + carboplatin vs. gemcitabine + carboplatin in the
               treatment of stage IIIB/IV NSCLC
        -- Large Meta-analysis of Diverse Patients with NSCLC
            -- Publication: 2007 ASCO Meeting Program
            -- Effect of race on the safety and efficacy of pemetrexed
               therapy in locally advanced and metastatic non-small cell lung
               cancer (NSCLC)
        -- Phase II Evaluation of ALIMTA Using Accelerated Vitamin
           Supplementation in Small Cell Lung Cancer
            -- Abstract # 7726: June 3, 2007: 8:00 a.m.
            -- The impact of shortened vitamin supplementation lead-in time
               before pemetrexed in patients with relapsed small cell lung
               cancer (SCLC)
        -- Early-phase Trial of ALIMTA +/- Steroids in Head & Neck Cancer
            -- Abstract # 6055: June 4, 2007: 1:00 p.m.
            -- A phase I dose escalation study of pemetrexed in patients with
               advanced head and neck squamous cell cancer
    -- GEMZAR(R) (gemcitabine HCl for injection)
        -- Phase III Study of GEMZAR Combination in Neoadjuvant
           (Pre-Surgical) Breast Cancer
            -- Abstract # 595: June 2, 2007; 2:00 p.m.
            -- Neoadjuvant chemotherapy with a dose-dense sequential
               combination of epirubicin and cyclophosphamide followed by
               paclitaxel and gemcitabine +/- trastuzumab in stage II and III
               breast cancer
    -- Enzastaurin
        -- Phase II Data of Targeted, Oral Agent enzastaurin in Second- &
           Third-line NSCLC
            -- Abstract # 7543: June 2, 2007; 8:00 a.m.
            -- A phase II study of enzastaurin as second- or third-line
               treatment of non-small cell lung cancer (NSCLC)
For more information on Lilly Oncology agents, including full
prescribing information, please see the attached fact sheet, or, if
you are receiving this electronically, you can view full prescribing
information on www.lillyoncology.com.
(Logo: http://www.newscom.com/cgi-bin/prnh/20031219/LLYLOGO)

Contact:

Gregory L. Clarke, +1-317-276-5222, or Mobile, +1-317-554-7119, or
Christine Van Marter, +1-317-651-1473, or Mobile, +1-317-554-7923,
both of Eli Lilly and Company; Photo: NewsCom:
http://www.newscom.com/cgi-bin/prnh/20031219/LLYLOGO, PRN Photo Desk,
photodesk@prnewswire.com

Plus de actualités: Eli Lilly and Company
Plus de actualités: Eli Lilly and Company
  • 16.04.2007 – 15:20

    Lilly and the AACR Work Together To Recognize Breakthrough Research in the Fight Against Cancer

    Los Angeles (ots/PRNewswire) - - Awards Presented for Substantial Contributions to Cancer Research Innovative and collaborative cancer research can be the catalyst to improving patient outcomes. Celebrating the 100th anniversary of the American Association for Cancer Research (AACR) at the 2007 AACR Annual Meeting in Los Angeles, Eli Lilly and Company in ...

  • 15.04.2007 – 15:03

    Lilly Oncology Focused on Pharmacogenomics at AACR Annual Meeting

    Los Angeles (ots/PRNewswire) - - Lilly Oncology to present more than a dozen studies designed to better predict patient outcomes Delivering on its commitment to relentless progress in cancer care; Lilly Oncology will present 17 studies at the 2007 American Association for Cancer Research (AACR) Annual Meeting in Los Angeles from April 14-18, 2007. Many of ...

  • 26.02.2007 – 12:05

    Lilly Plans New Clinical Trial of Xigris(R)

    Indianapolis (ots/PRNewswire) - - Trial will help better identify appropriate patient, define the benefit-risk profile in this population Eli Lilly and Company (NYSE: LLY) today announced plans for a new clinical study of Xigris(R) (drotrecogin alfa [activated]). The trial is designed to help clinicians better identify severe sepsis patients at high risk of death who are more likely to benefit from this ...